all report title image

P2X7 Receptor Antagonists Market, By Drugs (AKP-23494954/RQ-00466479, EVT 401, GSK1482160, JNJ-55308942, JNJ-54175446, and Others (e.g.- AZ11657312)), By Application (Central Nervous System Disorders, Immunological Disorders, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

  • Published In : 27 Jan, 2026
  • Code : CMI2595
  • Pages :154
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical
Ingographics Image

P2X7 receptor antagonists are still in the developmental stage and will require regulatory approval for introduction into the market. Manufacturers need to file an Investigational New Drug Application (IND) with the U.S. Food & Drug Application (FDA). Every drug is required to go through the approval process set by the FDA. P2X7 antagonists will be going through all the clinical trials after filing an Investigational New Drug (IND) application as any other new drug. However, the pharmaceutical organizations face several challenges for introducing these medications in the market due to a stringent regulatory approval process. These factors are considered in global P2X7 receptor antagonist market and factors affecting global P2X7 receptor antagonist market growth.

Market Dynamics

P2X7 Receptor Antagonists drug category is highly lucrative, as no drug therapies are available in this category. Leading organizations are investing in research and development of drugs in this category, which is expected to help market players in generating high revenue using patent protection. Disease and conditions such as major depressive disorders, mood disorders, chronic pain, and inflammation are highly prevalent and their incidence is also increasing. According to National Health Service Digital (NHS Digital), U.K., antidepressants medications prescriptions observed the largest increase in 2016, indicating the prevalence of depressive disorders. If launched, P2X7 receptor antagonists will be capable of acquiring a significant amount of market share for the disease or indication for which they have been approved. Drug manufacturers are also advancing the P2X7 antagonist drug category by developing innovative drugs such as AKP-23494954/RQ-00466479 (Asahi Kasei/RaQualia Pharma). These factors are expected to support global P2X7 receptor antagonist market growth over the forecast period.

Key features of the study

  • This report provides in-depth analysis of the P2X7 receptor antagonists market and provides market size (USD Mn) and compound annual growth rate (CAGR %) for the forecast period (2026–2033), considering 2025 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global P2X7 receptor antagonists market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
  • Key companies covered as a part of this study include, Asahi Kasei Corporation, GlaxoSmithKline Plc, Johnson & Johnson, AstraZeneca Plc, Evotec AG, and RaQualia Pharma
  • Insights from this report would allow marketers and the management authorities of companies to make informed decisions regarding their future product launches, by technology up-gradation, market expansion, and marketing tactics
  • The global P2X7 receptor antagonists market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the P2X7 receptor antagonists market

Market Segmentation

  • Drugs Insights (Revenue, USD Mn, 2026 - 2033)
    • AKP-23494954/RQ-00466479
    • EVT 401
    • GSK1482160
    • JNJ-55308942
    • JNJ-54175446
    • Others (e.g.- AZ11657312)
  • Application Insights (Revenue, USD Mn, 2026 - 2033)
    • Central Nervous System Disorders
    • Immunological Disorders
    • Others
  • Regional Insights (Revenue, USD Mn, 2026 - 2033)
    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa
  • Key Players Insights
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • AstraZeneca Plc
    • RaQualia Pharma
    • Evotec AG
    • Asahi Kasei Corporation

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drugs
      • Market Snippet, By Application
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Pipeline Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Impact Analysis
    • Key Developments
    • PEST Analysis
    • Epidemiology
  4. Global P2X7 Receptor Antagonists Market, By Drugs, 2026-2033 (USD Mn)
    • Introduction
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • AKP-23494954/RQ-00466479
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • EVT 401
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • GSK1482160
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • JNJ-55308942
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • JNJ-54175446
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • Others (e.g.- AZ11657312)
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
  5. Global P2X7 Receptor Antagonists Market, By Application, 2026-2033 (USD Mn)
    • Introduction
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • Central Nervous System Disorders
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • Immunological Disorders
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • Others
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
  6. Global P2X7 Receptor Antagonists Market, By Region, 2026–2033 (USD Mn)
    • Introduction
      • Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, For Region, 2021 - 2033
    • North America
      • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
      • Y-o-Y Growth Analysis, For Country, 2021 - 2033
      • Market Size and Forecast, By Drugs, 2026- 2033, (USD Mn)
      • Market Size and Forecast, By Application, 2026- 2033, (USD Mn)
      • Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
      • Y-o-Y Growth Analysis, For Country, 2021 - 2033
      • Market Size and Forecast, By Drugs, 2026- 2033, (USD Mn)
      • Market Size and Forecast, By Application, 2026- 2033, (USD Mn)
      • Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
        • Brazil
        • Argentina
        • Mexico
        • Rest of Latin America
    • Europe
      • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
      • Y-o-Y Growth Analysis, For Country, 2021 - 2033
      • Market Size and Forecast, By Drugs, 2026- 2033, (USD Mn)
      • Market Size and Forecast, By Application, 2026- 2033, (USD Mn)
      • Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
      • Y-o-Y Growth Analysis, For Country, 2021 - 2033
      • Market Size and Forecast, By Drugs, 2026- 2033, (USD Mn)
      • Market Size and Forecast, By Application, 2026- 2033, (USD Mn)
      • Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
      • Y-o-Y Growth Analysis, For Country, 2021 - 2033
      • Market Size and Forecast, By Drugs, 2026- 2033, (USD Mn)
      • Market Size and Forecast, By Application, 2026- 2033, (USD Mn)
      • Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • Market Share Analysis, By Country/Region, 2025, 2028 and 2033 (%)
      • Y-o-Y Growth Analysis, For Country/Region, 2021 - 2033
      • Market Size and Forecast, By Drugs, 2026- 2033, (USD Mn)
      • Market Size and Forecast, By Application, 2026- 2033, (USD Mn)
      • Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
        • South Africa
        • North Africa
        • Central Africa
  7. Competitive Landscape
    • Company Profiles
      • Asahi Kasei Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • GlaxoSmithKline Plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Johnson & Johnson
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • AstraZeneca Plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Evotec AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • RaQualia Pharma
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact
  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2026 Coherent Market Insights Pvt Ltd. All Rights Reserved.